Furthermore, growing evidence has displayed that blunting MAPK activities is an effective strategy to depress liver fibrosis via augmenting NF-κB inactivation and attenuating lipid accumulation (Abdelhamid et al., 2021; Wang et al., 2021). The gene discussed is NFKB1; the disease is Hepatic fibrosis.